Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert W. Duggan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 265
- Beta
- -1.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 41.77
Financials
Revenue
$0.00-100.0%Net Income
$-215.70MEBITDA
$-215.70MFree Cash Flow
$-168.75M-590.7%EPS (diluted)
$-0.28Shares Outstanding (diluted)
778.18M+1163.9%Operating Expenses
$220.50MCash & Debt
$690.68MReturn of Capital
$0.00Revenue by Segment (annual)
$4.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-1.08B | $-1.44 |
| 2024 | $0.00 | $-176.77M | $-0.25 |
| 2023 | $0.00 | $-482.37M | $-0.78 |
| 2022 | $583.2K | $-65.17M | $-0.34 |
| 2021 | $1.34M | $-65.52M | $-0.71 |
| 2020 | $628.9K | $-38.53M | $-0.55 |
| 2019 | $611.9K | $-23.99M | $-0.73 |
| 2018 | $57.09M | $10.87M | $0.11 |
| 2017 | $14.17M | $-20.16M | $-0.31 |
| 2016 | $2.38M | $-21.37M | $-0.35 |
| 2015 | $1.28M | $-20.14M | $-0.34 |
| 2014 | $1.89M | $-11.38M | $-0.29 |
| 2013 | $1.84M | $-6.09M | $-0.30 |
| 2012 | $1.90M | $-4.22M | $-0.27 |
Valuation
SMMThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (38)
- Newszacks.com·20h ago·Neutral
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.
View source ↗ - News (RSS)cityam·3d ago·Neutral
Chinese car sales top 300,000 in Britain this year as European rivals lose ground More than 300,000 Chinese cars have been sold in the UK so far this year, setting a fresh record as European rivals lose ground. Chinese carmakers made up five of the top 25-performing brands in the first nine months of the year, data from The Society of Motor Manufacturers and Traders (SMMT) has revealed, accounting [...]
View source ↗ - News (RSS)seekingalpha·4d ago·Neutral
AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo
View source ↗ - Newsgurufocus.com·4d ago·Neutral
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE:
View source ↗ - News (RSS)wsj·6d ago·Neutral
Health Care Roundup: Market Talk Find insight on Roche Holding, AstraZeneca’s investment in Summit Therapeutics, and more in the latest Market Talks covering Health Care.
View source ↗ - News (RSS)thisismoney·6d ago·Negative
AstraZeneca takes a £1.5bn stake in US cancer drug developer as it steps up investment in America The British drugs company has ploughed £1.5bn into US pharma firm Summit Therapeutics as part of a cancer treatment research joint venture.
View source ↗ - News (RSS)zerohedge·6d ago·Neutral
…x (NFLX) inches 1% higher after Deutsche Bank upgraded the streaming-video company to buy, saying that concerns about engagement were overblown. Summit Therapeutics (SMMT) rises 16% after AstraZeneca announced an investment in the biotech to collaborate on new cancer medication. Uniqure (QURE) slumps 58% after saying that the benefits of its Huntington’s disease gene therapy drug AMT-130 were not as good after four years as they were after three years in a small trial — a result that could compl…
View source ↗ - News (RSS)seekingalpha·6d ago·Neutral
Biggest stock movers Tuesday: SMMT, NVTS, and more
View source ↗ - News (RSS)cityam·7d ago·Negative
Astrazeneca invests $2bn in cancer drug tie-up Astrazeneca has invested $2bn in US pharmaceutical firm Summit Therapeutics as part of a blockbuster cancer research tie-up. The FTSE 100 drugs giant has agreed to buy 109,000 shares in Nasdaq-listed Summit for $18.36 per share as part of the deal. The tie-up will see the two pharma giants collaborate on a series of studies [...]
View source ↗ - News (RSS)economictimes·7d ago·Negative
Summit stock surges on $2 billion AstraZeneca investment AstraZeneca is investing $2 billion in Summit Therapeutics, taking a potential 12% stake and partnering on cancer-drug development, including ivonescimab, while investors await upcoming FDA regulatory decisions.
View source ↗ - News (Marketaux)gurufocus.com·7d ago·Positive
Summit Therapeutics (SMMT) Secures $2B AstraZeneca Investment, Shares Jump 17% On September 28, 2026, Summit <[+275 characters]
View source ↗ - News (RSS)barrons·7d ago·Negative
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
View source ↗ - News (RSS)wsj·7d ago·Negative
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
View source ↗ - News (RSS)seekingalpha·7d ago·Neutral
Summit Therapeutics rises after AstraZeneca commits $2B investment
View source ↗ - News (RSS)investing·7d ago·Neutral
AstraZeneca invests $2 billion in Summit Therapeutics
View source ↗ - News (Marketaux)gurufocus.com·15d ago·Neutral
Summit Therapeutics (SMMT) Shows Promise in Lung Cancer Trial but Faces Valuation Challenges On September 20, 2026, Summit <[+263 characters]
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Summit Therapeutics: It's Okay Not To Have An Answer
View source ↗ - News (Marketaux)gurufocus.com·20d ago·Neutral
Summit Therapeutics (SMMT) Reports Positive Phase III Survival Data Amid High Price-to-Sales Valuation On September 15, 2026, Summit <[+244 characters]
View source ↗ - Newsgurufocus.com·23d ago·Negative
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from
View source ↗ - Newsbusinesswire.com·23d ago·Negative
…y Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the Intern…
View source ↗ - News (RSS)yahoo·29d ago·Neutral
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
View source ↗ - Newszacks.com·31d ago·Negative
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
View source ↗ - News (RSS)seekingalpha·32d ago·Neutral
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.
View source ↗ - News (RSS)investing·32d ago·Neutral
Summit Therapeutics stock rises on positive survival data
View source ↗ - Newsbenzinga.com·32d ago·Positive
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading higher on Thursday after its development partner, Akeso Inc., reported highly favorable overall survival data from a late-stage clinical trial.
View source ↗ - Newsseekingalpha.com·33d ago·Positive
…nt For Summit Therapeutics' Cancer Bet Summit Therapeutics is positioned as a high-conviction buy into the November 2026 FDA PDUFA decision for ivonescimab in NSCLC. SMMT's ivonescimab demonstrates robust PFS and statistically significant OS benefits in multiple Phase III trials, supporting best-in-class potential versus PD-1 monotherapy. Financials reflect intentional capital deployment, with $690M+ cash and 4–5 quarters of runway to fund late-stage clinical catalysts and regulatory milestones.
View source ↗ - News (RSS)seekingalpha·33d ago·Negative
Summit Therapeutics in focus as its lung cancer drug shows survival benefit
View source ↗ - Newsbusinesswire.com·33d ago·Neutral
…ll Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung ca…
View source ↗ - Newszacks.com·39d ago·Positive
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.
View source ↗ - News (RSS)scmp·40d ago·Positive
…-head phase-three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and chemotherapy against...
View source ↗ - News (RSS)seekingalpha·40d ago·Positive
Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade) Summit Therapeutics, Inc. is upgraded to Buy as negative sentiment bottoms and catalysts approach, despite high volatility and cash burn. Ivonescimab demonstrated survival benefits in Chinese NSCLC and biliary tract cancer trials, with pivotal global data and FDA decisions pending. SMMT's liquidity covers 4–5 quarters, but aggressive pipeline expansion and high operating expenses raise going concern risks.
View source ↗ - Newsbenzinga.com·40d ago·Neutral
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy Summit Therapeutics Inc. (NASDAQ:SMMT) partner Akeso Inc. on Wednesday released positive topline findings from its randomized Phase 3 HARMONi-GI1 clinical trial (or AK112-309).
View source ↗ - News (RSS)zerohedge·40d ago·Neutral
… its experimental drug for rheumatoid arthritis, an autoimmune disease, fell short of the company’s internal bar to develop it as a monotherapy. Summit Therapeutics (SMMT) rises 8% after the cancer drug developer gave results from a late-stage trial of its experimental therapy, ivonescimab, as a treatment for biliary tract cancer. Analysts note that its the drug’s first success in a late-stage trial outside of lung cancer. Zoom Comons (ZM) falls 6% after the software company gave outlooks for ad…
View source ↗ - Newsbusinesswire.com·41d ago·Negative
…Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-regi…
View source ↗ - Newsbenzinga.com·41d ago·Neutral
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients Summit Therapeutics Inc. (NASDAQ:SMMT) announced that The Lancet Oncology published primary analysis results from its global Phase 3 HARMONi trial.
View source ↗ - Newsbusinesswire.com·54d ago·Neutral
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecifi
View source ↗ - News (RSS)thisismoney·58d ago·Negative
The most popular Chinese car brands in Britain: From small fry to the maker selling 1 in 25 of all new cars Based on the latest year-to-date figures SMMT, we've ranked Chinese carmakers by market share to see which has secured the largest slice of the UK automotive pie.
View source ↗
Earnings
Mon, Oct 19(in 13 days)
Consensus estimate $-0.28 per share
Typical surprise -2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$-0.28 vs $-0.27miss
- Thu, Apr 30$-0.24 vs $-0.33beat
- Mon, Feb 23$-0.29 vs $-0.10miss
- Mon, Oct 20$-0.31 vs $-0.18miss
- Mon, Aug 11$-0.76 vs $-0.09miss
- Thu, May 1$-0.09 vs $-0.09beat
Estimates and results for SMMT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SMMT officers and directors.
- Bought
- $175.1m
- Sold
- —
20 trades
0 trades
- Zanganeh Mahkamboughtdirector, 10 percent owner, officer: Co-Chief Executive Officer·3,810,000 @ $13.12·$50.0m·Jun 12, 2026·filing
- Duggan Robert Wboughtdirector, 10 percent owner, officer: Co-Chief Executive Officer·3,810,000 @ $13.12·$50.0m·Jun 12, 2026·filing
- Duggan Robert Wboughtdirector, 10 percent owner, officer: Co-Chief Executive Officer·100,000 @ $14.60·$1.5m·Jun 4, 2026·filing
- Zanganeh Mahkamboughtdirector, 10 percent owner, officer: Co-Chief Executive Officer·100,000 @ $14.60·$1.5m·Jun 4, 2026·filing
- Soni Manmeet Singhbought
- Soni Manmeet Singhbought
- Xia Yubought
- Duggan Robert Wboughtdirector, 10 percent owner, officer: Co-Chief Executive Officer·26,680 @ $18.74·$500k·Oct 21, 2025·filing
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SMMT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.